Quantcast

Latest Histone deacetylase Stories

Substance In Cancer Medicine May Help Prevent Heart Attacks
2011-11-24 06:00:51

Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden have been using a substance found in cancer and epilepsy drugs to help stimulate the body´s natural defense mechanism against blood clots. The body contains a system that helps break down blood clots before they can damage the heart, called the fibrinolytic system. This system “sprays” an enzyme on the clot before it can stop blood flow to the heart, causing a heart attack. This system can be...

2011-11-14 11:36:38

Clinical benefit from use of a novel histone deacetylase inhibitor drug may be determined by examining blood cells days after a patient receives treatment. The drug, entinostat, is the first histone deacetylase inhibitor successfully tested in a randomized, placebo-controlled study in metastatic breast cancer – and is the first to show that clinical outcome can be predicted shortly after administration. The findings, reported at the AACR-NCI-EORTC International Conference: Molecular...

2011-11-14 11:35:29

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer. They also found that introducing a novel histone deacetylase inhibitor in hormone therapy treatment can overcome resistance to hormonal therapy. "We always thought that resistance was primarily an inborn or genetic effect," said Pamela N. Munster, M.D., director of the Early-Phase Clinical...

2011-06-27 07:30:00

WALTHAM, Mass., June 27, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that data from two entinostat clinical trials both based on tumor reprogramming will be presented at the International Association for the Study of Lung Cancer's (IASLC) 14th World Conference on Lung Cancer meeting (www.2011worldlungcancer.org) July 3 to 7 in Amsterdam, The Netherlands. "The data presentations from both lung cancer programs at the...

2011-06-02 07:30:00

WALTHAM, Mass., June 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL--AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B." This follows the UK issuance which was granted in October of 2010 adding to the extensive patent estate. The patent covers the novel polymorph...

2011-05-31 13:32:58

A promising cancer treatment drug can restore function of a heart en route to failure from high blood pressure, researchers at UT Southwestern Medical Center have found. The drug, a type of histone deacetylase (HDAC) inhibitor being evaluated in numerous ongoing clinical trials, has been shown to reverse the harmful effects of autophagy in heart muscle cells of mice. Autophagy is a natural process by which cells eat their own proteins to provide needed resources in times of stress. The new...

2011-05-04 06:00:00

SINGAPORE, May 4, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009. As a result, S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx. Following a successful and productive partnership with Onyx, S*BIO will now be in a position to drive the development of its lead JAK2 program independently. Recent data...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.